Here's a note from Alan W. Partin, MD, PhD, Chief Urologist and Director of the Department of Urology at Johns Hopkins. He's a famous research scientist known for the Partin Tables among other things. He thinks the STAMPEDE trial that showed the superiority of ADT (e.g., Lupron) + abiraterone (Zytiga) over ADT alone is the top story in prostate cancer for 2017.
I started this as a clinical trial about 7 months ago along with a test medication (apalutimide). So far my PSA dropped from 18 to 0.6, my lymph nodes shrunk to normal size and no cancer cells identified in blood stream. I hope this works for a while!
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.